Save as Favorite
Sign in to receive recommendations (Learn more)

Lynparza (chemical name: olaparib) was approved by the U.S. Food and Drug Administration (FDA) on Jan. 12, 2018 to treat metastatic HER2-negative breast cancer with an inherited BRCA1 or BRCA2 mutation that has previously been treated with chemotherapy.

Lynparza is a pill taken by mouth. The recommended starting dose of Lynparza is 300 mg taken twice per day, with or without food.

In this section you can learn more about:

Was this article helpful? Yes / No

Eoy18 sidebar 1
Back to Top